300. IgG4関連疾患 ［臨床試験数：31，薬物数：33（DrugBank：16），標的遺伝子数：11，標的パスウェイ数：81］
Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||JPRN-UMIN000022633||2016/06/06||06/06/2016||Efficacy and safety of low-dose steroid treatment in asymptomatic patients with autoimmune pancreatitis.||autoimmune pancreatitis||Steroid treatment (total 56 weeks)|
Induction ~ 4 weeks : Prednisolone 10mg/day
4 weeks ~ 48 weeks : Prednisolone 5mg/day
48 weeks ~ 52 weeks : Prednisolone 2.5mg/day
52 weeks ~ 56 weeks : Prednisolone 1mg/day
|Osaka University||NULL||Pending||20years-old||Not applicable||Male and Female||20||Not selected||Japan|
|2||JPRN-UMIN000003804||2010/05/01||25/06/2010||Randomized controlled trial which examines whether resuming steroid can prevent clinical relapse in the patients with asymptomatic high levels of serum IgG after ceasing steroid therapy for autoimmune pancreatitis||autoimmune pancreatitis||Prednisolone at a dose of 10mg/day is started. The dose is taperd by 2.5mg every 8-10 weeks until reaching 5mg/day.|
Maintenance therapy at a dose of 5 mg/day is continued.
Resuming or increasing prednisolone is not planned. Patients during the course of tapering prednisolone continue to taper the dose until its complete cessation.
|Department of Gastroenterology, University of Tokyo||NULL||Recruiting||20years-old||Not applicable||Male and Female||20||Not applicable||Japan|